Adam Feuerstein, STAT

Adam Feuerstein

STAT

Boston, MA, United States

Contact Adam

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

Recent:
  • STAT
Past:
  • CNBC
  • Business Insider
  • The Boston Globe
  • Fox News
  • TheStreet

Recent articles by Adam:

An Anavex study spin job sullies an otherwise spectacular Alzheimer's conference

With a shameless spin job, Anavex Life Sciences once again showed its willingness to misrepresent clinical trial results, @adamfeuerstein writes. → Read More

Listen: Whither PhRMA, Alzheimer’s treatment data revealed, and the first fecal microbiome drug approval

A big Alzheimer's treatment data reveal. The first FDA-approved fecal microbiome drug. And a stinging defeat for Big Pharma's lobbying arm. We cover all that and more on this week's episode of “The Readout LOUD” #podcast. → Read More

FDA approves a gene therapy for the inherited bleeding disorder hemophilia B

The FDA approved the first gene therapy to treat people with hemophilia B, an inherited bleeding disorder. It will cost $3.5 million, making it the most expensive drug approved to date. → Read More

GSK to withdraw blood cancer drug from U.S. market following confirmatory study setback

British pharma giant GSK said Tuesday that it will withdraw its blood cancer drug Blenrep from the U.S. market, following a request from the Food and Drug Administration. → Read More

Northwest Bio study of brain cancer vaccine still falls short

Northwest Biotherapeutics tried again, but its experimental treatment for brain cancer still falls short. → Read More

Merck to acquire Imago, bolstering pipeline for drugs targeting bone marrow diseases

Merck said Monday that it is acquiring Imago BioSciences for $1.35 billion, adding experimental drugs that target bone marrow diseases to its research pipeline. → Read More

Pfizer CEO says Covid vaccine will remain ‘free for all Americans,’ overlooking indirect costs

Pfizer's CEO says the company's Covid vaccines will remain "free for all Americans" — an assertion that overlooked indirect costs that will be passed on to consumers. → Read More

Listen: Roche’s failure, Eisai’s success, and a live AMA

How do Alzheimer’s drugs even work? Can biotech people bake? And do we even like one another? All that and more on "The Readout LOUD" #podcast this week. Listen now: → Read More

‘We were right all along:’ For Japanese drugmaker Eisai, success against Alzheimer's has been a long time coming

The success of the Alzheimer's treatment lecanemab gives Eisai a chance to make good on years of fruitless labor and to resolve what one executive described as “unfinished business.” → Read More

Immunogen wins FDA approval for targeted medicine to treat advanced ovarian cancer

Immunogen's new drug, called Elahere, is the first new treatment option for advanced ovarian cancer to reach the U.S. market in more than seven years. → Read More

Despite higher dose, Stoke Therapeutics drug not active enough against childhood epilepsy

Stoke Therapeutics said that a higher dose of its experimental drug for epilepsy reduced the frequency of convulsive seizures in children with a rare form of the disease. However, the treatment effect was still too low to provide a meaningful benefit. → Read More

Roche’s experimental Alzheimer’s treatment fails to slow cognitive decline across two clinical trials

An investigational Alzheimer’s disease treatment from Roche slowed the rate of cognitive decline by 8% and 6% in two clinical trials, Roche said Monday, failing to meeting the goals of two large studies → Read More

Biogen’s new CEO, clear-eyed about company’s challenges, prepares to take the reins

“I’m not the type of guy to go run something that is smoothly running,” said Biogen's new CEO, Christopher Viehbacher. → Read More

Listen: Biogen’s new CEO, how the midterms affect science, & a biotech bankruptcy

How can Biogen right the ship? What happened to that "red wave"? And what can NASCAR teach us about public health? Find out on the latest episode of "The Readout LOUD" #podcast. → Read More

Biogen appoints former Sanofi executive Christopher Viehbacher as CEO

Biogen named Christopher Viehbacher, who formerly ran the French drug giant Sanofi, as its new CEO on Thursday. → Read More

Seagen names longtime Novartis exec as new CEO

Seagen has named pharmaceutical industry executive David Epstein as its new leader to replace Clay Siegall, who resigned in May → Read More

Clovis Oncology warns of likely bankruptcy filing following years of scandal and financial losses

Clovis Oncology, a maker of cancer drugs, warned that it will likely file for bankruptcy protection due to dwindling sales of its sole product, mounting financial losses and a crushing debt load. → Read More

Shares of Merrimack, a dormant drugmaker, soar after cancer drug succeeds in trial

Shares of Merrimack Pharmaceuticals, a shuttered drugmaker, more than doubled Wednesday because of a $225 million windfall that it will receive due to the success of a treatment for pancreatic cancer. → Read More

J&J’s Mammen out of the running for Biogen CEO post

Biogen is mulling new options in its search for a CEO after talks with a senior research executive from Johnson & Johnson reached an impasse, STAT has learned. → Read More

FDA places clinical hold on Verve Therapeutics gene-edting treatment

Verve Therapeutics said its experimental gene-editing treatment for a common form of heart disease was placed on clinical hold by the Food and Drug Administration, potentially delaying an ongoing, early-stage clinical trial. → Read More